Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 1 - 20 of 225
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-100225-PIP01-21-M03 (update)
  • PARATHYROID HORMONE
  • Treatment of hypoparathyroidism
  • Natpar
  • Natpar
  • Natpar
  • Endocrinology-Gynaecology-Fertility-metabolism
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101761-PIP01-24
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2)
  • Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage)
  • Prevention of influenza infection
  • Adjuvanted Trivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus suspension for injection in pre-filled syringe
  • Fluad
  • Fluad
  • Fluad
  • Fluad
  • Fluad
  • Fluad
  • Fluad
  • Vaccines
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101789-PIP01-25
  • Vixarelimab
  • Treatment of idiopathic pulmonary fibrosis (IPF)
  • Pneumology - Allergology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101752-PIP01-24
  • BELZUTIFAN
  • Treatment of neuroendocrine tumours
  • Welireg
  • Welireg
  • Welireg
  • Welireg
  • Welireg
  • Welireg
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101750-PIP01-24
  • Tenapanor
  • Treatment of hyperphosphataemia
  • Xphozah
  • Phozevel
  • Uro-Nephrology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100326-PIP02-24
  • Gemcitabine (hydrochloride)
  • Treatment of malignant bladder neoplasms
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100311-PIP02-24
  • Cetrelimab
  • Treatment of malignant bladder neoplasms
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101604-PIP01-24
  • efgartigimod alfa
  • Treatment of Sjögren's disease
  • Vyvgart
  • Vyvgart
  • Immunology -Rheumatology-Transplantation
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101771-PIP01-24
  • SEMAGLUTIDE
  • Prevention of cardiovascular events in patients with atherosclerosis
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Rybelsus
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101718-PIP01-24
  • Human alpha-1-proteinase inhibitor immunoglobulin G fusion protein, recombinant
  • Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin
  • Pneumology - Allergology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101704-PIP01-24
  • Nucresiran sodium
  • Treatment of transthyretin amyloidosis
  • Neurology
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101676-PIP01-24
  • HUMAN ANTI-D IMMUNOGLOBULIN
  • Prevention of Rhesus (Rh) isoimmunisation
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Immunorho
  • Haematology-Hemostaseology
  • Other: Immunology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101674-PIP01-24
  • Linvoseltamab
  • Treatment of multiple myeloma
  • LYNOZYFIC
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101707-PIP01-24
  • AMG 193
  • Treatment of non-small cell lung cancer
  • Not available at present
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101729-PIP01-24
  • Ifinatamab deruxtecan
  • Treatment of prostate malignant neoplasms
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101730-PIP01-24
  • Ifinatamab deruxtecan
  • Treatment of oesophageal cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101660-PIP01-24
  • RUXOLITINIB PHOSPHATE
  • Treatment of prurigo nodularis
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • OPZELURA
  • Dermatology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101412-PIP01-24
  • Pridopidine hydrochloride
  • Treatment of amyotrophic lateral sclerosis (ALS)
  • Nurzigma
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101770-PIP01-24
  • SEMAGLUTIDE
  • Treatment of Chronic Kidney Disease
  • Ozempic
  • Ozempic
  • Ozempic
  • Ozempic
  • Ozempic
  • Uro-Nephrology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101694-PIP01-24
  • Human IgG1 monoclonal antibody targeting amyloid transthyretin
  • Treatment of transthyretin-mediated amyloidosis
  • Neurology
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No